KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed scientific literature. KAI’s program is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.KAI-1678 has been shown to be highly effective at reversing pain in preclinical models of both neuropathic and inflammatory pain. KAI-1678 also was shown to reverse pain more effectively than gabapentin, an industry-standard comparison in pain research.
KAI is currently enrolling patients in multiple phase 2a clinical studies.
Approximately 50 million people in the United States suffer from some form of persistent pain, while another 25 million suffer acute pain each year as a result of injury or surgery.1 According to a survey by the American Pain Society, four out of ten people suffering moderate-to-severe pain were unable to find adequate pain relief. There is a major need for novel therapeutics with unique mechanisms of action that provide effective pain relief with reduced side effects. Current treatments for pain, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), can be limited by serious side effects and inadequate efficacy.
1 Source: Jain PharmaBiotech, 2003
|
